144
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Impact of the COVID-19 Pandemic on Emergency Department Visits - United States, January 1, 2019-May 30, 2020.

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          On March 13, 2020, the United States declared a national emergency to combat coronavirus disease 2019 (COVID-19). As the number of persons hospitalized with COVID-19 increased, early reports from Austria (1), Hong Kong (2), Italy (3), and California (4) suggested sharp drops in the numbers of persons seeking emergency medical care for other reasons. To quantify the effect of COVID-19 on U.S. emergency department (ED) visits, CDC compared the volume of ED visits during four weeks early in the pandemic March 29-April 25, 2020 (weeks 14 to 17; the early pandemic period) to that during March 31-April 27, 2019 (the comparison period). During the early pandemic period, the total number of U.S. ED visits was 42% lower than during the same period a year earlier, with the largest declines in visits in persons aged ≤14 years, females, and the Northeast region. Health messages that reinforce the importance of immediately seeking care for symptoms of serious conditions, such as myocardial infarction, are needed. To minimize SARS-CoV-2, the virus that causes COVID-19, transmission risk and address public concerns about visiting the ED during the pandemic, CDC recommends continued use of virtual visits and triage help lines and adherence to CDC infection control guidance.

          Related collections

          Most cited references2

          • Record: found
          • Abstract: found
          • Article: not found

          Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment–Elevation Myocardial Infarction Care in Hong Kong, China

          Acute ST-segment–elevation myocardial infarction (STEMI) is a disease of high mortality and morbidity, and primary percutaneous coronary intervention (PPCI) is the typical recommended therapy. 1,2 Systems of care have been established to expedite PPCI workflow to minimize ischemic time from symptom onset to definitive treatment in the catheterization laboratory. Little is known about the impact of public health emergencies like a community outbreak of infectious disease on STEMI systems of care. Since December 2019, the emergence of Coronavirus disease 2019 (COVID-19) in Wuhan, China, has evolved into a regional epidemic, including in Hong Kong, a city in Southern China. We describe the impact of the COVID-19 outbreak on STEMI care in Hong Kong through a handful of recent cases of patients with STEMI who underwent PPCI at a single center. We included patients with STEMI admitted via the Accident and Emergency Department and in whom PPCI was performed. We focus on the time period since January 25, 2020, when hospitals in the city started to institute emergency infection protocols to contain COVID-19. This required hospitals to suspend all nonessential visits and adjust clinical in-patient and out-patient services. Indications for PPCI were according to the international guidelines. 1,2 Study exclusion criteria included inpatient STEMI (n=1), STEMI with unknown symptom onset time (n=3), and cardiac arrest patients (n=2). Our hospital has offered 24/7 PPCI service to all eligible patients presenting with acute STEMI since 2010 per standard Accident and Emergency Department protocol. When STEMI is diagnosed, a PPCI team is activated after cardiology evaluation. Data on key time points in STEMI care are recorded in a clinical registry. Symptom-onset-to-first-medical-contact time is defined as the time from patient-reported chest discomfort onset time to the time of first medical contact. Door-to-device time is defined as the time from Accident and Emergency Department arrival to successful wire crossing time during PPCI. Catheterization laboratory arrival-to-device time is defined as the time from patient arrival in the catheterization laboratory to successful wire crossing time. From January 25, 2020, to February 10, 2020, we observed changes in time components of STEMI care among the aggregate group of 7 consecutive patients who underwent PPCI. We compared these with data from 108 patients with STEMI treated with PPCI in the prior year from February 1, 2018, to January 31, 2019 (N=108). These 7 patients did not suffer from COVID-19 infection, and 6 out of 7 presented to our hospital during regular work hours (8 am–8 pm weekdays, excluding public holidays). The Table shows numerically longer median times in all components when compared with historical data from the prior year. The largest time difference was in the time from symptom onset to first medical contact. Table. Time Components of STEMI Care Before and After COVID-19 Outbreak The extent to which a community outbreak of infection like COVID-19 stresses other parts of healthcare system like STEMI care is largely unknown. Contemporary COVID-19 infection affects respiratory tract and is capable of human-to-human transmission presumably via droplets. 3,4 Given these concerns, Hong Kong hospitals implemented stringent infection control measures starting in late January 2020, including but not limited to universal masking, full personal protective equipment (N95 respirator, goggles/face shield, isolated gown, disposable gloves) for aerosol-generating procedures, frequent environmental disinfection, suspension of ward visit, volunteer service, and clinical attachment. Of course, these protocols are essential for limiting the spread of infections like COVID-19 but also may impact healthcare systems in unexpected ways. Most visibly, we found large delays in the small number of patients with STEMI seeking medical help after institution of these infection control measures. It is understandable that people are reluctant to go to a hospital during the COVID-19 outbreak, which explains the potential delays in seeking care. Another concern that we are unable to evaluate is whether some patients with STEMI did not seek care at all. Delays in seeking care or not seeking care could have a detrimental impact on outcomes. We also found delays in evaluating patients with STEMI after hospital arrival that could be explained by several reasons. For example, catheterization laboratories generally have positive pressure ventilation so COVID-19 infection inside these rooms can theoretically cause widespread contamination of the surrounding environment. Precautions such as detailed travel and contact history, symptomatology, and chest X-ray, therefore, are taken before transferring patients to the catheterization laboratory at our hospital. Although these are essential measures for containing COVID-19 infection, this could increase delays in diagnosis, staff activation and transfer if healthcare systems are not prepared. Similarly, even after patients arrived in the catheterization laboratory, staff may need more time to wear protective gear to prepare the patients and interventional cardiologists may not be used to performing PPCI while in full protective gear, leading to longer treatment. This is a preliminary report, and our study should be considered in the context of the following limitations. We describe a single hospital’s experience in STEMI care after instituting emergency infection protocols in a handful of patients. It is possible that patients and staff improve over time as their experiences with these measures mature. Although we cannot make meaningful statistical complications, our description allows for an early examination into how public health emergencies can indirectly affect unrelated hospital areas. In modern society, infectious agents like the COVID-19 outbreak can spread quickly and evolve into a pandemic. Hospitals not only need to consider methods for containing and treating these infections but how infection outbreaks may affect systems of care beyond the immediate infection. Acknowledgment We would like to thank all healthcare workers who have sacrificed themselves in the current coronavirus disease-19 (COVID-19) outbreak. Disclosures None.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage

            We conducted a nationwide retrospective survey on the impact of COVID-19 on the diagnosis and treatment of acute cornary syndrome (ACS) from 2 to 29 March in Austria. Of the 19 public primary percutaneous coronary (PCI) centres contacted, 17 (90%) provided the number of admitted patients. During the study period, we observed a significant decline in the number of patients admitted to hospital due to ACS (Figure 1 ). Comparing the first and last calendar week, there was a relative reduction of 39.4% in admissions for ACS. In detail, from calendar week 10 to calendar week 13, the number of ST-segment elevation myocardial infarction (STEMI) patients admitted to all hospitals was 94, 101, 89, and 70, respectively. The number of non-STEMI patients declined even more markedly from 132 to 110, to 62, and to 67. Figure 1 Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19. The absolute numbers of all ACS (blue bars), STEMI (orange bars), and NSTEMI (grey bars) admissions in Austria from calendar week 10 to calendar week 13 are shown. Abbreviations: STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction. The main finding of our retrospective observational study is an unexpected major decline in hospital admissions and thus treatment for all subtypes of ACS with the beginning of the COVID-19 outbreak in Austria and subsequent large-scale public health measures such as social distancing, self-isolation, and quarantining. Several factors might explain this important observation. The rigorous public health measures, which are undoubtedly critical for controlling the COVID-19 pandemic, may unintentionally affect established integrated care systems. Amongst others, patient-related factors could mean that infarct-related symptoms such as chest discomfort and dyspnoea could be misinterpreted as being related to an acute respiratory infection. Moreover, the strict instructions to stay at home as well as the fear of infection in a medical facility may have further prevented patients with an ACS from going to a hospital. Irrespective of the causes, the lower rate of admitted and therefore treated patients with ACS is worrisome and we are concerned that this might be accompanied by a substantial increase in early and late infarct-related morbidity and mortality. Our study does not provide data on mortality; however, considering the annual incidence of ACS in Austria (200/100 000/year = 17 600/year in 8.8 million habitants) 1 and taking into consideration sudden cardiac deaths and silent infarctions (one-third), there will remain ∼1000 ACS cases a month. The difference between the assumed number of ACS patients and the observed number in our study, i.e. 725 ACS patients in calendar weeks 10–13 is 275. According to these assumptions, 275 patients were not treated in March 2020. Based on data showing that the cardiovascular mortality of untreated ACS patients might be as high as 40% (as it was in the 1950s), 2 we can theoretically estimate 110 ACS deaths during this time frame. The number of deaths associated with this unintentional undersupply of guideline-directed ACS management is very alarming, particularly when considering that the official number of COVID-related deaths in Austria was 86 on 29 March. In conclusion, it seems likely that the COVID-19 outbreak is associated with a significantly lower rate of hospital admissions and thus, albeit unintended, treatment of ACS patients, which is most likely explained by several patient- and system-related factors. Every effort should be undertaken by the cardiology community to minimize the possible cardiac collateral damage caused by COVID-19.
              Bookmark

              Author and article information

              Journal
              MMWR Morb Mortal Wkly Rep
              MMWR. Morbidity and mortality weekly report
              Centers for Disease Control MMWR Office
              1545-861X
              0149-2195
              Jun 12 2020
              : 69
              : 23
              Article
              10.15585/mmwr.mm6923e1
              7315789
              32525856
              1662ace6-3c7a-4897-a459-2a5345f8501a
              History

              Comments

              Comment on this article